Hematologic Diseases: Clinical Trials

275 trials for Hematologic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

275 terminated. 275 Phase 3, 30 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3275Terminated 275
Phase 230Terminated 30

Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases

Trials (filtered) newest first · largest first

All 275 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial
SerpinPC - Hemophilia a, Hemophilia B
Phase 3TerminatedApcinteX Ltd152024-07-112025-02-10
Phase III Long-Term Extension Study With Dexpramipexole
Dexpramipexole Dihydrochloride - Eosinophilic Asthma
Phase 3TerminatedAreteia Therapeutics5092024-06-122025-12-15
Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery
Coagulation Factor VIIa (Recombinant) - Hemophilia
Phase 3TerminatedLaboratoire français de Fractionnement et de Biotechnologies22024-06-072026-07-31
ATG Plus Low-dose PT-Cy for GVHD Prevention
Cyclophosphamid, ATG - Hematologic Malignancy
Phase 3TerminatedPeking University People's Hospital662023-11-012025-06-03
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Asciminib, Imatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive
Phase 3TerminatedSarit Assouline82023-11-012026-05-29
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) - Myelodysplastic Syndromes(MDS)
Phase 3TerminatedTJ Biopharma Co., Ltd.102023-03-302025-04-27
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic
Phase 3TerminatedAreteia Therapeutics6542023-03-272025-12-15
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD) - Multiple Myeloma
Phase 3TerminatedUniversitätsklinikum Hamburg-Eppendorf282023-03-032026-01-05
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic
Phase 3TerminatedAreteia Therapeutics10612023-01-302025-12-15
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG) - Severe Aplastic Anemia
Phase 3TerminatedBoston Children's Hospital532023-01-252026-10-19
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
Osivelotor - Sickle Cell Disease
Phase 2 / Phase 3TerminatedPfizer472023-01-052026-03-19
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
Cemdisiran, Eculizumab, Pozelimab - Paroxysmal Nocturnal Hemoglobinuria
Phase 3TerminatedRegeneron Pharmaceuticals32022-10-062025-04-08
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Magrolimab, Venetoclax, Azacitidine - Acute Myeloid Leukemia
Phase 3TerminatedGilead Sciences3782022-07-072025-04-04
Voxelotor Neurocognitive Function Study
Voxelotor Only Product in Oral Dose Form, Placebo - Sickle Cell Disease
Phase 3TerminatedPfizer12022-06-242024-05-02
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
Rivaroxaban 10 MG, Placebo - Sickle Cell Disease, Central Venous Catheter Thrombosis
Phase 3TerminatedUniversity Health Network, Toronto42022-06-072025-03-19
Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy
Iron Isomaltoside 1000, ferric derisomaltose, Iron sucrose - Iron Deficiency Anaemia in Childbirth
Phase 3TerminatedSaskatchewan Health Authority - Regina Area1132022-06-062026-11-19
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
Evusheld (tixagevimab+cilgavimab) IM or IV - SARS-CoV-2 Infection
Phase 3TerminatedMediMergent, LLC5502022-06-032023-09-08
Resolution of Sickle Cell Leg Ulcers With Voxelotor
Voxelotor Oral Tablet, Placebo - Sickle Cell Disease, Leg Ulcers
Phase 3TerminatedPfizer882022-05-302025-07-09
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
Inclacumab - Sickle Cell Disease, Vaso-occlusive Crisis
Phase 3TerminatedPfizer2412022-03-292026-11-19
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis
Phase 3TerminatedPfizer722021-12-092024-12-11

Showing 20 of 275. Sign in to see all of them.

Narrower conditions

Anemia (34)  ·  Leukemia, Myeloid, Acute (34)  ·  Anemia, Sickle Cell (28)  ·  Multiple Myeloma (28)  ·  Myelodysplastic Syndromes (23)  ·  Leukemia (22)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (17)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (17)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (15)  ·  Hemophilia A (14)  ·  Neoplasms (14)  ·  Thrombocytopenia (13)  ·  Myeloproliferative Disorders (12)  ·  Hematologic Neoplasms (10)

Broader conditions

Hemic and Lymphatic Diseases (275)  ·  Neoplasms (117)  ·  Neoplasms by Histologic Type (110)  ·  Pathological Conditions, Signs and Symptoms (82)  ·  Immune System Diseases (80)  ·  Pathologic Processes (72)  ·  Immunoproliferative Disorders (64)  ·  Leukemia (63)  ·  Lymphoproliferative Disorders (63)  ·  Hemorrhagic Disorders (62)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (58)  ·  Cardiovascular Diseases (52)  ·  Disease Attributes (51)  ·  Genetic Diseases, Inborn (51)

Interventions

Cyclophosphamide (17)  ·  Dexamethasone (17)  ·  Azacitidine (12)  ·  Cytarabine (12)  ·  Epoetin Alfa (11)  ·  Bortezomib (8)  ·  Busulfan (7)  ·  Etoposide (7)  ·  Imatinib Mesylate (7)  ·  fludarabine (7)  ·  Calcium Dobesilate (6)  ·  Darbepoetin alfa (6)  ·  Methotrexate (6)  ·  Rituximab (6)  ·  Thalidomide (6)

Sponsors

Novartis Pharmaceuticals (10)  ·  Gilead Sciences (9)  ·  Pfizer (9)  ·  Hoffmann-La Roche (8)  ·  Amgen (5)  ·  Baxalta now part of Shire (4)  ·  European Society for Blood and Marrow Transplantation (4)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4)  ·  M.D. Anderson Cancer Center (4)  ·  Merck Sharp & Dohme LLC (4)  ·  AMAG Pharmaceuticals, Inc. (3)  ·  Actelion (3)  ·  Areteia Therapeutics (3)  ·  AstraZeneca (3)  ·  Bio Products Laboratory (3)

Countries

United States (158)  ·  Germany (71)  ·  France (67)  ·  United Kingdom (61)  ·  Canada (60)  ·  Italy (60)  ·  Spain (51)  ·  Poland (45)  ·  Belgium (42)  ·  Australia (35)  ·  Russia (33)  ·  Israel (32)  ·  South Korea (31)  ·  Czechia (30)  ·  Netherlands (29)

Top investigators

Margaret V Ragni, MD, MPH (3)  ·  Russell E. Ware, MD, PhD (3)  ·  Avroy A. Fanaroff, MD (2)  ·  Bart Barlogie, MD, PhD (2)

Results publications

PMID 36791280, PMID 20175775, PMID 39393433, PMID 33275766, PMID 34219224, PMID 37703506, PMID 40277027, PMID 10802492, PMID 11416871, PMID 11824975, PMID 12966125, PMID 14510322, PMID 14993550, PMID 15050885, PMID 15226337, PMID 15247354, PMID 15803929, PMID 16553139, PMID 17307536, PMID 17312332, PMID 17985376, PMID 17999759, PMID 18477354, PMID 18838471, PMID 19109560, PMID 19270260, PMID 20231680, PMID 20850381, PMID 21233311, PMID 21325604, PMID 21394050, PMID 21459791, PMID 21503695, PMID 21826782, PMID 21837771, PMID 21848879, PMID 22271702, PMID 22315495, PMID 22318199, PMID 22658895, PMID 22674807, PMID 22913681, PMID 22959335, PMID 23216616, PMID 23248249, PMID 23278371, PMID 2334081, PMID 23462431, PMID 23515925, PMID 23539110

NIH funding

2019 (10), 2015 (8), 2018 (4), 2023 (4), 2005 (3), 2016 (3), 2008 (2), 2014 (2), M01RR000070 (2), M01RR000750 (2), M01RR000997 (2), M01RR001032 (2), M01RR006022 (2), M01RR008084 (2), U01HD019897 (2)